PMID- 26989658
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160318
LR  - 20220321
IS  - 2235-1795 (Print)
IS  - 1664-5553 (Electronic)
IS  - 1664-5553 (Linking)
VI  - 5
IP  - 1
DP  - 2016 Feb
TI  - Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with 
      Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON 
      Registry.
PG  - 37-46
LID - 10.1159/000367757 [doi]
AB  - BACKGROUND: Global Investigation of Therapeutic Decisions in Hepatocellular 
      Carcinoma and of Treatment with Sorafenib (GIDEON) is a worldwide, prospective, 
      non-interventional study to evaluate the safety of sorafenib in a variety of 
      patient subsets. METHODS: Eligible patients had unresectable hepatocellular 
      carcinoma for whom the decision had been made to treat with sorafenib. Treatment 
      strategies were instituted at the physician's discretion. Patient and disease 
      characteristics, treatment practices, incidences of adverse events (AEs), and 
      overall survival were collected. RESULTS: In the United States, 563 patients were 
      evaluable for safety. Subgroup analysis was performed for patients who underwent 
      transarterial chemoembolization (TACE) prior to the initiation of sorafenib 
      (group A, n=158), after the initiation of sorafenib only (group B, n=29), both 
      (group C, n=38), or did not undergo TACE (n=318). Patient demographics were 
      similar across the groups. In group A, 29% had Child-Pugh score B or C at 
      diagnosis, and 19% had Barcelona Clinic Liver Cancer tumor stage C or D. In group 
      B, 48% had Child-Pugh score B or C at study entry, and 31% had BCLC stage C or D. 
      The majority of patients in all groups initially received full-dose sorafenib. 
      Incidences of grade >/=3 drug-related AEs were 30%, 17%, and 16% in groups A, B, 
      and C, respectively, and 22% in patients who did not undergo TACE. No new safety 
      signals emerged. CONCLUSIONS: The results from GIDEON reaffirm that sorafenib can 
      be safely used in the context of TACE.
FAU - Geschwind, Jean-Francois H
AU  - Geschwind JF
AD  - Radiology and Oncology, Department of Radiology and Imaging Sciences, Yale 
      University School of Medicine, NewHaven, Conn., USA.
FAU - Gholam, Pierre M
AU  - Gholam PM
AD  - Case Western Reserve University, Liver Center of Excellence, University Hospitals 
      Case Medical Center, Cleveland, Ohio, USA.
FAU - Goldenberg, Alec
AU  - Goldenberg A
AD  - NYU Medical School, New York, N.Y., USA.
FAU - Mantry, Parvez
AU  - Mantry P
AD  - The Liver Institute, Methodist Dallas Medical Center, Dallas, Tex., USA.
FAU - Martin, Robert C G
AU  - Martin RC
AD  - Division of Surgical Oncology, University of Louisville, Louisville, Ky., USA.
FAU - Piperdi, Bilal
AU  - Piperdi B
AD  - Montefiore Medical Center, Bronx, N.Y., USA.
FAU - Zigmont, Ellen
AU  - Zigmont E
AD  - Onyx Pharmaceuticals, South San Francisco, Calif., USA.
FAU - Imperial, Joanne
AU  - Imperial J
AD  - FibroGen, Inc, San Francisco, Calif., USA.
FAU - Babajanyan, Svetlana
AU  - Babajanyan S
AD  - Bayer HealthCare Pharmaceuticals, Whippany, N.J., USA.
FAU - Foreman, Pamela K
AU  - Foreman PK
AD  - Blue Ocean Pharma LLC, Annandale, N.J., USA.
FAU - Cohn, Allen
AU  - Cohn A
AD  - Rocky Mountain Cancer Center, US Oncology, Denver, Colo., USA.
LA  - eng
PT  - Journal Article
DEP - 20151215
PL  - Switzerland
TA  - Liver Cancer
JT  - Liver cancer
JID - 101597993
PMC - PMC4789900
OTO - NOTNLM
OT  - GIDEON
OT  - Hepatocellular carcinoma
OT  - Sorafenib
OT  - TACE
OT  - Transarterial chemoembolization
EDAT- 2016/03/19 06:00
MHDA- 2016/03/19 06:01
PMCR- 2015/12/15
CRDT- 2016/03/19 06:00
PHST- 2016/03/19 06:00 [entrez]
PHST- 2016/03/19 06:00 [pubmed]
PHST- 2016/03/19 06:01 [medline]
PHST- 2015/12/15 00:00 [pmc-release]
AID - lic-0005-0037 [pii]
AID - 10.1159/000367757 [doi]
PST - ppublish
SO  - Liver Cancer. 2016 Feb;5(1):37-46. doi: 10.1159/000367757. Epub 2015 Dec 15.